Drugs / tyrosinase 368-376 (370D)
last change Jun 2005 re-read 2 minutes ago

tyrosinase 368-376 (370D)

Peptide

Developed for
melanoma
Investigated by
University of Southern California

Trials 1 · a red edge is where a trial was stopped

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00028431 Aug 2001 → Jan 2003 melanoma University of Southern California Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as tyrosinase 368-376 (370D) “The peptides are tyrosinase 368-376 (370D); gp100 209-217 (210M); and MART-1 26-35 (27L) which are emulsified with IFA.” NCT00028431
Modality Peptide “The peptides are tyrosinase 368-376 (370D); gp100 209-217 (210M); and MART-1 26-35 (27L) which are emulsified with IFA.” NCT00028431